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Abstract
Objective
To address the variability in prevalence estimates and inconsistencies in potential risk factors
for poststroke cognitive impairment (PSCI) using a standardized approach and individual
participant data (IPD) from international cohorts in the Stroke and Cognition Consortium
(STROKOG) consortium.
Methods
We harmonized data from 13 studies based in 8 countries. Neuropsychological test scores 2 to 6
months after stroke or TIA and appropriate normative data were used to calculate standardized
cognitive domain scores. Domain-speciﬁc impairment was based on percentile cutoﬀs from
normative groups, and associations between domain scores and risk factors were examined with
1-stage IPD meta-analysis.
Results
In a combined sample of 3,146 participants admitted to hospital for stroke (97%) or TIA (3%),
44% were impaired in global cognition and 30% to 35% were impaired in individual domains 2
to 6 months after the index event. Diabetes mellitus and a history of stroke were strongly
associated with poorer cognitive function after covariate adjustments; hypertension, smoking,
and atrial ﬁbrillation had weaker domain-speciﬁc associations. While there were no signiﬁcant
diﬀerences in domain impairment among ethnoracial groups, some interethnic diﬀerences were
found in the eﬀects of risk factors on cognition.
Conclusions
This study conﬁrms the high prevalence of PSCI in diverse populations, highlights common
risk factors, in particular diabetes mellitus, and points to ethnoracial diﬀerences that warrant
attention in the development of prevention strategies.
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While poststroke cognitive impairment (PSCI) is mild in
many stroke survivors, numerous studies have reported
a prevalence of dementia in poststroke cases that varies from
7.4% in a population-based study of ﬁrst stroke to 41.3% in
hospital-based cases of recurrent stroke.1 The prevalence
may diﬀer by geographic region, diagnostic criteria, and
methods of assessment. Because the severity of cognitive
impairment in poststroke patients is on a continuum, how-
ever, it is arguably more meaningful to use a standardized
continuous measure to examine cognitive impairment rather
than the diagnosis of dementia.2 Because of the heteroge-
neity of stroke and its eﬀects on cerebral function, the cog-
nitive proﬁle of poststroke dementia is understandably
complex. There is evidence that some cognitive domains, in
particular complex attention, working memory, and frontal
executive function, are aﬀected early in vascular dementia.3
Poststroke dementia, however, is also associated with lan-
guage and visuospatial dysfunction, even though individuals
with severe language impairment are often excluded from
detailed investigations.4 In addition, studies of cognitive
proﬁle have largely been conducted in white, non-Hispanic
populations, and it is uncertain whether the same pattern is
seen in Asian and African populations.
The clinical determinants of PSCI remain incompletely un-
derstood. While older age and low levels of education have
consistently emerged as risk factors,5 various other putative
risk factors have been inconsistently reported, including risk
factors for cerebrovascular disease (e.g., hypertension, diabetes
mellitus, atrial ﬁbrillation [AF], smoking), prior pathology
(e.g., previous stroke, Alzheimer disease), APOE genotype,
stroke features, and lesion characteristics.6 The variability of
the ﬁndings has prevented a consensus from being reached on
the most relevant factors in predicting the development of
poststroke dementia.7 The Stroke and Cognition Consortium
(STROKOG), an international consortium of studies of
cognitive decline and dementia after stroke or TIA, oﬀers an
opportunity to address the inconsistencies in prevalence esti-
mates and potential risk factors for PSCI.8 This article presents
a comprehensive proﬁle of the cognitive performance of
patients 2 to 6 months after stroke or TIA and explores the
associations between a variety of risk factors and impairment
in cognitive function. We hypothesized that the prevalence of
Glossary
AF = atrial ﬁbrillation; CHF = congestive heart failure; DSM-IV = Diagnostic and Statistical Manual of Mental Disorders, 4th
edition; IPD = individual participant data; MI = myocardial infarction; NEMESIS = North East Melbourne Stroke Incidence
Study; PROSPER = Prospective Study of Pravastatin in the Elderly at Risk; PSCI = poststroke cognitive impairment; SAM =
Helsinki Stroke Aging Memory Study; STROKDEM = Study of Factors Inﬂuencing Post-Stroke Dementia; STROKOG =
Stroke and Cognition Consortium.
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PSCI will be high across diﬀerent geographical regions but will
vary across diﬀerent ethnoracial groups. We also hypothesized
that PSCI aﬀects diﬀerent cognitive domains equally and that
vascular risk factors for stroke are also risk factors for PSCI
independently of the occurrence of stroke.
Methods
Inclusion criteria
STROKOG member studies with detailed neuropsychological
assessments 2 to 6months after stroke/TIA that agreed to share
data in 2016 were included. Studies were required to have
recruited a control group, provided data for an appropriate
comparison group (e.g., from a representative local study), or
provided standardized test scores that were adjusted for sex, age,
and education using an appropriate comparison group. A ﬂow
diagram showing studies that were included is given in appendix
F1 available from Dryad (doi.org/10.5061/dryad.m517990).
Contributing studies
Thirteen studies fromAfrica (1), Asia (4), Australia (2), Europe
(5), and the United States (1) contributed data (table 1). Three
studies enrolled patients with TIA (clinically diagnosed and
conﬁrmed by a neurologist), and 9 studies excluded partic-
ipants with preexisting dementia (i.e., previously diagnosed
or based on the Informant Questionnaire on Cognitive De-
cline in the Elderly at recruitment; an overview of study re-
cruitment strategies and inclusion and exclusion criteria is
provided in appendixes T1 and T3 available from Dryad, doi.
org/10.5061/dryad.m517990). All studies except the North
East Melbourne Stroke Incidence Study (NEMESIS; com-
munity cohort) and Prospective Study of Pravastatin in the
Elderly at Risk (PROSPER; randomized controlled trial)
were hospital-based observational studies of consecutively
admitted patients with stroke or TIA (table 1). The Study of
Factors Inﬂuencing Post-Stroke Dementia (STROKDEM)
was the only study to exclude participants with dementia after
the index stroke. Not including PROSPER, 5 studies
Table 1 Contributing studies
Study Abbreviation Country No.a
Year
study began
Type of study/
population
Time between
index event and
assessment, mo
Bundang Vascular Cognitive
Impairment Cohort
Bundang VCI Korea 660 2007 Observational/
hospital
3
Cognition and Affect After Stroke:
Prospective Evaluation of Risks
CASPER The Netherlands 250 2013 Observational/
hospital
3
Cognitive Outcome After Stroke COAST Singapore 326 2009 Observational/
hospital
3–6
Cognitive Function After Stroke
Nigeria
CogFAST-
Nigeria
Nigeria 143 2010 Observational/
hospital
3
Epidemiologic Study of the Risk of
Dementia After Stroke
EpiUSA United States 453 1988 Observational/
hospital
3
Groupe de Re´flexion pour
l’evaluation Cognitive Vasculaire
Study
GRECogVASC France 200 2010 Observational/
hospital
6
Korean-Vascular Cognitive
Impairment Harmonization
Standards Study
K-VCIHS Korea 353 2007 Observational/
hospital
3
North East Melbourne Stroke
Incidence Study
NEMESIS Australia 99 1998 Observational/
community
3
National Neuroscience Institute
Study
NNI Singapore 185 2011 Observational/
hospital
2–6
Prospective Study of Pravastatin in
the Elderly at Risk
PROSPER Ireland,
Scotland, the
Netherlands
130 1993 Randomised
clinical trial/
primary care
1–6
Helsinki Stroke Aging Memory
Study
SAM Finland 409 1993 Observational/
hospital
3
Sydney Stroke Study SSS Australia 167 1997 Observational/
hospital
3–6
Study of Factors Influencing Post-
Stroke Dementia
STROKDEM France 145 2011 Observational/
hospital
6
a Sample size used for the Stroke and Cognition Consortium (STROKOG) project, not of the study itself. For study details, see appendixes T1 through T3
available from Dryad (doi.org/10.5061/dryad.m517990).
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recruited their own control group of stroke-free volunteers
without serious illnesses from the surrounding community.
Other studies provided data or calculated standardized test
scores on the basis of population-based studies that consisted
of local stroke-free volunteers, except for STROKDEM,
which used published local normative data (brief descriptions
of each study and control group details are given in appen-
dixes T2 and T4 available from Dryad). All studies provided
individual participant data (IPD) except PROSPER and
Helsinki Stroke Aging Memory Study (SAM), an observa-
tional study fromHelsinki, both of which conducted in-house
analyses using a protocol prepared for this project.
Standard protocol approvals, registrations,
and patient consents
Procedures of the consortium have been approved by the
University of New South Wales Human Research Ethics
Committee (reference HC14359). All studies had ethics ap-
proval from local institutional review boards.
Demographics and medical history
Patient demographic variables included age, sex, and educa-
tion level, with education converted into a 4-category variable
(details on how education level data were harmonized are
given in appendix T5 available from Dryad, doi.org/10.5061/
dryad.m517990). Most cohorts consisted predominantly of 1
ethnoracial group; for the harmonization of ethnicity, we
classiﬁed white participants from all Western studies as white
but kept separate each of the Asian and African American/
Nigerian subgroups (details on how ethnicity data were har-
monized are given in appendix T6 available from Dryad). For
the baseline stroke/TIA event (the index event), 6 studies
included ischemic stroke only; other studies included a small
number of TIAs and/or hemorrhagic strokes. Regarding
stroke characteristics, we examined stroke subtype and stroke
laterality. Those characteristics were determined on the basis
of the results of routine structural brain imaging, typically CT
scans for older studies and MRI for more recent studies,
considered alone or in combination with the results of the
neurologic examination and other medical workups. Stroke
subtype was coded into 6 categories, with 5 ischemic stroke
subtypes—large artery, small vessel, cardioembolic, other
determined (ischemic), and undetermined (ischemic)—and
hemorrhagic stroke (subtypes of hemorrhagic stroke were not
included due to small numbers; details on the original classi-
ﬁcation used in each study and how they were harmonized are
given in appendix T7 available from Dryad). Stroke laterality
refers to cerebral strokes only and was coded as left hemi-
sphere, right hemisphere, or bilateral (brainstem/cerebellar
strokes were not included). Each study recorded diﬀering sets
of putative risk factors, with important cardiovascular risk
factors such as a history of hypertension, type 2 diabetes
mellitus, AF, past stroke (before the index event), and
smoking (past or present), collected by most studies. A subset
of studies collected data on congestive heart failure (CHF),
angina, and myocardial infarction (MI), but no other risk
factors were collected by >2 studies. Medical conditions were
as noted in medical records except for in SAM, which used
speciﬁc clinical criteria (appendix T2 available from Dryad).
Statistical methods
Cognitive profile and prevalence of impairment
To harmonize the diﬀerent neuropsychological tests con-
ducted by all studies, we calculated standardized scores, ad-
justed for age, sex, and education. This approach, described in
a review of harmonization methods as standardization by
the use of T scores,9 closely parallels the common neuro-
psychological practice of interpreting test scores using stan-
dardized values obtained from normative data provided in test
manuals. First, we standardized raw test scores into z scores
based on the control group of the study (details regarding the
method used for calculating z scores in each study are given in
appendix A2.2 available from Dryad, doi.org/10.5061/dryad.
m517990).9,10 The z scores were adjusted for sex, age, and
education with a regression method. We then assigned each
test to 1 of 5 cognitive domains: attention and processing speed
(attention), memory, language, perceptual motor, or frontal
executive function (executive function), according to common
practice11 and previous work.12 We calculated domain z scores
as standardizedmeans of all test z scores in a domain; the global
cognition score was the standardized mean of the 5 cognitive
domains. Methodologic details and the list of neuro-
psychological tests used in each domain in each study are
available from Dryad (appendixes A2 and T10).
Participants with z scores <6.68th percentiles (equivalent to
<1.5 SDs for normally distributed scores) in the comparison
group were considered impaired in a domain. The 2.28th
percentile (2 SDs) was used as a more stringent criterion for
severe impairment. For studies without comparison group
data, cut points were estimated from the averages from studies
with available data (appendix A3 available from Dryad, doi.
org/10.5061/dryad.m517990). We calculated overall pro-
portions of impairment by stroke subtype, side of stroke, and
ethnoracial groups, and diﬀerences between subgroups were
explored with χ2 tests.
In addition, we used mixed-eﬀects logistic regression models
to explore the association between ethnicity and impairment,
with study as a random eﬀect. Only ethnoracial groups rep-
resented by ≥2 studies were included in these analyses to
ensure that more general conclusions about ethnoracial
groups could be drawn.
Vascular risk factors and cognitive function
The relationship between risk factors and cognitive func-
tion was examined with 1-stage IPD meta-analysis using
linear mixed models, with study as the random eﬀect.13
Each model includes global cognition or 1 of the 5 cogni-
tive domain scores as the outcome variable, with adjust-
ment for sex, age (in years), and education (in 4
categories). In the ﬁrst step, each risk factor was modeled
separately as the independent variable. In the second step
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and main set of analyses, risk factors (hypertension, di-
abetes mellitus, smoking, AF, smoking, past stroke) were
included together in a single multivariable model. In the
third step, stroke subtype was added, and the Baron and
Kenny14 approach was used to examine possible mediation
by stroke subtype (methodological details are given in
appendix A4.1 available from Dryad, doi.org/10.5061/
dryad.m517990).
We did not adjust for other covariates (e.g., APOE) because of
missing data for many studies. Collinearity was checked by
examining the correlation between risk factors and calculating
the variance inﬂation factor for each independent variable in
the model. The main analysis (step 2) was examined in ad-
dition with the 2-stage IPD meta-analysis to produce forest
plots and the heterogeneity measure I2.15 Linear regression
models were used to produce eﬀect estimates of risk factors in
each study, and results were combined by use of random-
eﬀects models. Further analyses were conducted with both
stroke and control groups. We examined whether the eﬀects
of risk factors diﬀered between these groups by including
interactions (stroke status × risk factor) in the models (ap-
pendix A4.2 available from Dryad, doi.org/10.5061/dryad.
m517990).
All analyses
We did not include NEMESIS and PROSPER in the com-
bined sample because they were not hospital-based studies.
Therefore, for all patients in the combined sample, neuro-
psychological assessments were performed 2 to 6 months
after stroke (refer to the ﬂowchart in appendix F1 available
from Dryad, doi.org/10.5061/dryad.m517990). STROK-
DEM was not included in the proﬁle analysis because it
excluded participants with dementia after the index stroke.
Because SAM did not provide IPD and conducted analyses
independently, we combined those summary results with
ours using meta-analytic methods.13 For all analyses, global
cognition was considered the primary measure for cognitive
function, and the signiﬁcance level was assessed at the 0.05
level (2 sided); the 5 domains were secondary measures,
and Bonferroni correction was applied for multiple com-
parisons across cognitive domains (α [adjusted] = 0.01). All
analyses were performed with Stata 14.1 (StataCorp, Col-
lege Station, TX). The Preferred Reporting Items for
a Systematic Review and Meta-Analysis IPD checklist was
used for reporting.16
Data availability
Anonymized data will be shared on request from any qualiﬁed
investigator.
Results
Sample characteristics
Maximum sample size was 3,520 from 13 studies with 61%
male, average age 67.0 years (SD = 11.1), and 44% white (see
table 2 for other patient characteristics in the combined
sample and in individual studies). Most patients (92%) had
had an ischemic stroke, 4.7% TIA, and 1.8% hemorrhagic
stroke (table 3; additional data on stroke and risk factor
characteristics are available in appendix T8 from Dryad, doi.
org/10.5061/dryad.m517990).
Cognitive profile and prevalence
of impairment
For the combined sample (n = 2,698), mean z scores for the 5
domains were similar at approximately −1 SD, and mean
global cognition was −1.5 SDs; 44% of patients were impaired
in global cognition, and between 30% and 35% were impaired
across the 5 domains 2 to 6 months after stroke or TIA (table
4). Figure 1 shows the percentage of impairment in each
domain in each study, with full results available from Dryad
(appendix T11, doi.org/10.5061/dryad.m517990). Studies
not included in the combined sample had the lowest pro-
portions of impairment (1%–19% across domains). When the
more stringent criterion of the 2.28th percentile was used, the
proportion of impairment was ≈10% less across all domains,
with a similar pattern of impairment observed across studies.
If we take out the 3 studies (n = 1,198) that did not exclude
preexisting dementia, the overall proportion of impairment
was 42% in global cognition and 25% to 35% in individual
domains, with no more than a 5% diﬀerence compared to the
percentages observed in the combined sample.
Dementia was originally diagnosed with a variety of methods,
including DSM-IV and Vascular Behavioral and Cognitive
Disorders criteria (summaries available in appendixes T9 and
T12 from Dryad, doi.org/10.5061/dryad.m517990), in 3% to
26% of patients and mild cognitive impairment in 26% to 67%
in studies that were included in the combined sample. For
studies with no missing domain scores, 37% to 61% had im-
pairment in ≥2 domains and 56% to 79% had impairment in
≥1 domains. For each study, the proportion of those clinically
diagnosed with dementia or mild cognitive impairment was
comparable to the proportion of patients impaired in ≥1
domains (results available from Dryad, appendix T12).
Proportions of impairment were signiﬁcantly greater in left
hemisphere stroke compared to right hemisphere stroke in
global cognition (p = 0.004), memory (p < 0.001), language
(p < 0.001), and executive function (p < 0.001) (results
showing the proportions of impairment in each domain by
side of stroke are available from Dryad, appendix T13, doi.
org/10.5061/dryad.m517990). Impairment was greater in
right hemisphere stroke compared to left hemisphere stroke
in perceptual motor function, but the statistical signiﬁcance
was borderline (p = 0.026; results available from Dryad, ap-
pendix T13). In terms of stroke subtype, strokes related to
small vessel disease etiology had lower proportions of im-
pairment compared to other subtypes in global cognition (p <
0.001) and all domains except memory; impairment pro-
portions were greater for cardioembolic strokes vs others in
global cognition (p = 0.007), language, and executive function
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Table 2 Characteristics of participants with stroke/TIA from contributing studies
Bundang
VCI CASPER COAST
CogFAST-
Nigeria Epi USA GRECogVASC K-VCIHS NEMESIS NNI PROSPER SAM SSS STROKDEM All studies
No. 660 250 326 143 453 200 353 99 185 130 409 167 145 3,520
Age, y 67.7 (10.5) 67.5 (12) 59.8 (11) 60.3 (9.5) 71.9 (8.3) 65.1 (10.3) 64.5 (13) 70.5 (14) 57.7 (11) 75.4 (3.4) 70.7 (7.7) 72.1 (9.1) 63.3 (13) 67.0 (11.1)
Age range, y 22–91 42–91 23–94 45–84 59–96 41–81 12–93 28–98 30–85 70–82 55–85 49–86 25–87 12–98
Male, n (%) 414 (63) 161 (64) 229 (70) 81 (57) 215 (47) 121 (61) 216 (61) 58 (59) 128 (69) 71 (55) 202 (49) 104 (62) 92 (63) 2,092 (59)
Education, y 10.0 (5.4) NA 7.7 (4.3) 9.3 (5.6) 10.1 (4.9) 10.3 (3.0) NA 9.7 (2.3) 9.3 (3.3) 15.4 (2.15)* 9.2 (4.1) 10.6 (3.1) 11.3 (4.0) 9.5 (4.4)
Less than high
school
completion,
n (%)
327 (50) 102 (41) 199 (61) 80 (56) 243 (54) 150 (75) 286 (81)c 68 (69) 71 (39) NA 225 (55) 118 (71) 88 (61) 1,957 (58)
High school
completion,
n (%)
125 (19) 82 (33) 60 (18) 16 (11) 104 (23) 19 (10) NAc 17 (17) 71 (39) NA 35 (9) 10 (6) 18 (12) 557 (16)
Technical or
college
diploma,
n (%)
45 (6.8) 17 (6.8) 51 (16) 26 (18) 39 (9) 17 (9) 67 (19)c 14 (14) 38 (21) NA 96 (23) 24 (14) 16 (11) 450 (13)
Bachelor’s
degree and
above, n (%)
163 (25) 47 (19) 16 (5) 21 (15) 67 (15) 14 (7) NAc 0 4 (2) NA 53 (13) 15 (9) 23 (16) 423 (12)
Ethnicitya Korean White Singaporean
Chinesea
Nigerian 43% White;
44% African
Americanb
White Korean White Singaporean
Chinesea
White White White White 44% White; 29% Korean;
11% Chinese; 6% African
American; 4% Nigerian
Abbreviations: CASPER =Cognition and Affect After Stroke: Prospective Evaluation of Risks; COAST =Cognitive OutcomeAfter Stroke; COGFAST-Nigeria = Cognitive Function After StrokeNigeria; EpiUSA = Epidemiologic Study of
the Risk of Dementia After Stroke; GECOG-VASC, Groupe de Re´flexion pour l’evaluation Cognitive Vasculaire Study; K-VCIHS = Korean-Vascular Cognitive Impairment Harmonization Standards Study; NA = not applicable;
NEMESIS =North EastMelbourne Stroke Incidence Study; NNI =National Neuroscience Institute Study; PROSPER =Prospective Study of Pravastatin in the Elderly at Risk; SAM=Helsinki Stroke AgingMemory Study; SSS = Sydney
Stroke Study; STROKDEM = Study of Factors Influencing Post-Stroke Dementia; VCI = Vascular Cognitive Impairment.
Figures are number (percent) or mean (SD) unless specified. Details on the coding of education are available from Dryad (appendix T5, doi.org/10.5061/dryad.m517990).
* The mean age at which the participants left school; they were not included in the combined group.
a For ethnicity, the study cohort wasmade up entirely or predominately of the ethnicity shown unless otherwise specified. COAST study included Singaporean Chinese (72%),Malaysians (19%) and South Asians (8%); for theNNI
study, cohort consisted of Singaporean Chinese (85%) and Malaysians (11%).
b The white and African American groups consisted of 33% Hispanics.
c K-VCIHS recorded education in categories that did not distinguish between high school dropouts and completers, and the technical or college diploma category included those with more than 12 years of education.
e2262
N
eu
ro
logy
|
Vo
lu
m
e
93,N
um
b
er
24
|
D
ecem
b
er
10,2019
N
eurology.org/N
Table 3 Risk factors and stroke event of participants with stroke/TIA from each study
Bundang
VCI CASPER COAST
CogFAST-
Nigeria Epi USA GRECogVASC K-VCIHS NEMESIS NNI PROSPER SAM SSS STROKDEM All studies
No. 660 250 326 143 453 200 353 99 185 130 409 167 145 3,520
Medical history, n (%)
Hypertension 477 (72) 180 (72) 233 (71) 132/141 (94) 331 (73) 125 (63) 222 (63) 57 (58) 143 (77) 71 (55) 199 (49) 94/159
(59)
78 (54) 2,611/3,508
(74)
Diabetes mellitus 186 (28) 37 (15) 129 (40) 34/139 (24) 156 (34) 45 (23) 114 (32) 16 (16) 60 (32) 18 (14) 96 (24) 23/157
(15)
17 (12) 931/3,505
(27)
Atrial fibrillation 99 (15) 24 (9.8) 35 (11) 5/137 (4) 58/451
(13)
24 (12) 54 (15) NC 28 (15) NC 80/408
(20)
38/156
(24)
16 (11) 437/3,019
(14)
History of past stroke 73 (11 16 (6.4) 64/326
(20)a
18/136 (13) 109/451
(24)
15 (8) 64 (18) 0 28 (15) 28 (22) 77 (19) 22/156
(14)
14 (10) 528/3,498
(15)
Smoking (ever) 247 (45) 186 (74) 133 (41) 28/136 (21) 262/448
(58)
72 (36) 161 (46) 60 (60) 79 (43) 92 (71) 222/399
(56)
94/160
(59)
31 (21) 1,667/3,382
(49)
Index event (at
baseline), n (%)
b b b b
Ischemic stroke 660 (100) 233 (93) 254 (78) 116 (81) 453 (100) 180 (90) 353
(100)
88 (89) 185
(100)
43 (33) 409 (100) 135 (81) 144 (99) 3,253 (92)
Hemorrhagic stroke 0 15 (6) 0 16 (11) 0 20 (10) 0 11 (11) 0 2 (1.5) 0 0 1 (0.7) 65 (1.8)
TIA 0 0 72 (22) 0 0 0 0 0 0 60 (46) 0 32 (19) 0 164 (4.7)
Abbreviations: CASPER =Cognition and Affect After Stroke: Prospective Evaluation of Risks; COAST =Cognitive OutcomeAfter Stroke; COGFAST-Nigeria = Cognitive Function After StrokeNigeria; EpiUSA = Epidemiologic Study of
the Risk ofDementia After Stroke; GECOG-VASC, GroupedeRe´flexion pour l’evaluation Cognitive Vasculaire Study; K-VCIHS =Korean-Vascular Cognitive Impairment Harmonization Standards Study; NC=not counted; NEMESIS
= North East Melbourne Stroke Incidence Study; NNI = National Neuroscience Institute Study; PROSPER = Prospective Study of Pravastatin in the Elderly at Risk; SAM = Helsinki Stroke AgingMemory Study; SSS = Sydney Stroke
Study; STROKDEM = Study of Factors Influencing Post-Stroke Dementia; VCI = Vascular Cognitive Impairment.
Figures are number (percent) if there are no missing values. For those with missing values, number/sample with available data (percent) is shown instead.
a Includes TIA.
b In CASPER, 2 had unknown lesion type. In CogFAST-Nigeria, 11 had undetermined stroke type. In PROSPER, 25 patients had unknownmechanism for stroke event. In total, there were 38 (1%) patients with stroke of unknown
type.
N
eurolo
gy.o
rg/N
N
eurology
|
Volum
e
93,N
um
b
er
24
|
D
ecem
b
er
10,2019
e2263
(results available from Dryad, appendix T13). There was no
signiﬁcant diﬀerence in impairment between ischemic and
hemorrhagic strokes (p = 0.34 for global cognition).
Regarding ethnoracial groups, we observed the highest pro-
portion of global impairment in African Americans (48%, 1
study), followed by whites (47%, 5 studies), Koreans (45%, 2
studies), Nigerians (40%, 1 study), and Singaporean Chinese
(35%, 2 studies; results showing the proportions of impair-
ment by ethnoracial groups are available from Dryad, ap-
pendix T14, doi.org/10.5061/dryad.m517990). Pairwise
comparison showed signiﬁcant diﬀerences between Koreans
and Chinese and between whites and Chinese in certain
domains (results available from Dryad, appendix T14).
However, mixed models (before covariate adjustments) did
not reveal any signiﬁcant relationships between ethnoracial
groups and impairment.
Vascular risk factors and cognitive function
Diabetes mellitus was strongly associated with poorer per-
formance in global cognition and in all domains when ex-
amined independently (table 5) and after adjustment for
other risk factors (−0.47 SD; p < 0.001 in global cognition; full
results available fromDryad, appendix T15, doi.org/10.5061/
dryad.m517990). Similarly, a history of stroke was associated
with poorer global cognition (−0.45 SD; p < 0.001) and
Figure 1 Stacked bar chart showing the percentage of impairment in each domain in each study
Each column does not add up to 100%. Impairment is based on the 6.68th percentile. COAST = Cognitive Outcome After Stroke; EpiUSA = Epidemiologic Study
of the Risk of Dementia After Stroke; GRECogVASC = Groupe de Re´flexion pour l’evaluation Cognitive Vasculaire Study; K-VCIHS = Korean-Vascular Cognitive
Impairment Harmonization Standards Study; SAM = Helsinki Stroke Aging Memory Study; SSS = Sydney Stroke Study; VCI = Vascular Cognitive Impairment.
*Studies with missing domain score. **Studies not included in the combined sample.
Table 4 Cognitive domain profile for the combined sample
Combined sample
Attention and
processing speed Memory Language
Perceptual
motor
Frontal executive
function
Global
cognition
z Score −0.98 (1.80) −0.84 (1.45) −1.00 (1.51) −1.03 (1.70) −1.10 (1.72) −1.47 (1.91)
Impaired (6.68th
percentile), n (%)
907/2,841 (32) 873/2,903 (30) 1,044/3,086 (34) 871/2,577 (34) 977/2,825 (35) 1,381/3,116 (44)
Very impaired (2.28th
percentile), n (%)
669/2,841 (24) 519/2,903 (18) 723/3,086 (23) 544/2,577 (21) 741/2,825 (26) 995/3,116 (32)
The z scores with normal distributions are shown as mean (SD). The impairment figures are the number of participants impaired out of the number of
participants with available data (e.g., who completed tests in a domain), with corresponding percent. Results on the cognitive profile for each study are
available from Dryad (appendix T7, doi.org/10.5061/dryad.m517990). Combined sample includes 10 studies (excluding North East Melbourne Stroke
Incidence Study [NEMESIS], Prospective Study of Pravastatin in the Elderly at Risk [PROSPER], and Study of Factors Influencing Post-Stroke Dementia
[STROKDEM]).
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impairment in all domains except memory. Although the
eﬀects were smaller, hypertension was also associated with
poorer global cognition, language, and executive function
when examined independently, and it remained signiﬁcantly
related to global cognition after adjustment (−0.16 SD; p =
0.02). Patients with AF had poorer global cognition, atten-
tion, and executive function after adjustment (−0.26 SD; p =
0.005 for global). Past or current smoking was a signiﬁcant
risk factor for perceptual motor impairment (−0.24 SD; p =
0.001), but it was not signiﬁcantly related to global cognition
(−0.13 SD; p = 0.06).
When examined alone on the basis of 5 studies, CHF was
strongly associated with poorer cognitive function in global
cognition and in all domains (table 5), but it was not signif-
icant after adjustment for other risk factors (results available
from Dryad, appendix T16, doi.org/10.5061/dryad.
m517990). On the basis of 4 studies, we found no signiﬁcant
association between angina or MI and cognition (p = 0.98 and
0.91, respectively, for global cognition; table 5).
After further adjustment for stroke subtype, the results for
all risk factors remained unchanged except for AF, the eﬀect
of which on global cognition changed from −0.26 SD (p =
0.005) to nearly zero (0.02; p = 0.90; results available from
Dryad, appendix T17, doi.org/10.5061/dryad.m517990).
Because AF is associated with larger infarcts, we tested
for the mediation eﬀects of cardioembolic stroke vs other
subtypes. Results showed that conditions for full mediation
were met, with the eﬀect of AF on cognition reduced
to nearly zero (−0.03; p = 0.84; the steps and results of
the mediation analysis are available from Dryad, appen-
dix A4.1).
We further explored 2-way interactions among risk factors
and between a risk factor and demographic factors, and none
was signiﬁcant (results available in appendix T18 from
Dryad, doi.org/10.5061/dryad.m517990). However, there
were signiﬁcant interactions with ethnoracial groups: di-
abetes mellitus, past stroke, and smoking were associated
with poorer performance in global cognition, attention, and
memory, respectively, in Koreans compared to whites
(−0.74 vs −0.32 SD; p = 0.013 for diabetes mellitus and
global cognition). The association of smoking with executive
function was weaker in Chinese compared to Koreans (p =
0.0008), and the association of AF with memory was weaker
in Chinese compared to whites (p = 0.005; full results
available from Dryad, appendix T19).
In 2 separate sensitivity analyses that ﬁrst excluded 104 (4%)
patients with TIA and then excluded 3 studies that did not
exclude patients with preexisting dementia (n = 1,198), the
results were very similar to our key ﬁndings, with eﬀect sizes
changing by <5% in either direction in the ﬁrst analysis and 15%
in the second. In the analysis that included controls to examine
whether the eﬀects of risk factors were the same in stroke and
control groups, none of the interaction terms was signiﬁcant.
Heterogeneity among studies was low in most of the meta-
analyses (I2 = 0%–49%); for AF and past stroke, heteroge-
neity was moderate and signiﬁcant in certain domains (I2 =
50%–63%; p < 0.05; for global cognition, refer to ﬁgure 2; the
rest of the forest plots are available from Dryad, appendix F2,
doi.org/10.5061/dryad.m517990). However, heterogeneity
was reduced in the analysis of AF with stroke subtype as an
additional adjustment: I2 was reduced from 54.2% (p = 0.016)
to 26.8% (p = 0.20) for global cognition. For a history of
stroke, we conducted a sensitivity analysis by removing
studies with eﬀect sizes that deviated >1 SD from the pooled
eﬀect. This did not change the signiﬁcant association of past
stroke with poorer cognition.
Discussion
This article presents a large-scale examination by an in-
ternational consortium of the eﬀects of stroke on cognitive
function using IPD and a standardized approach to char-
acterizing cognitive impairment. While we did not generate
dementia diagnoses because too few studies had item-level
data available on instrumental activities of daily living
scales, we have instead presented a comprehensive char-
acterization of cognitive performance in patients after
stroke.
Our results showed that impairment was common and gen-
eralized, with proportions of impaired patients varying from
30% to 35% in each cognitive domain, even though other
studies showed a preponderance of disturbance in the
domains of attention/processing speed and frontal executive
function.4 Although memory impairment was not a salient
feature in our cohort, in the absence of biomarkers, potential
contributions from Alzheimer disease and other neurode-
generative pathologies to cognitive impairment in our cohort
cannot be dismissed.
We have shown that patients with stroke related to small
vessel disease etiology had signiﬁcantly less impairment than
patients with other stroke subtypes 2 to 6 months after stroke.
Smaller stroke volume in those with stroke related to small
vessel disease compared to other etiologies may be associated
with a lower proportion of impairment, and the use of detailed
imaging data would be beneﬁcial in further investigating this
ﬁnding in future studies. Cerebral small vessel disease often
causes stroke, however, and a review has suggested that as-
sociated small vessel disease may increase the eﬀect of stroke
on cognitive function,17 an eﬀect that might be observed with
longer follow-up.
As expected, there was a greater proportion of impairment in
patients with left hemisphere stroke vs those with right
hemisphere stroke in the language domain. In addition,
greater impairment in patients with left hemisphere stroke in
memory and executive function can be explained by the fact
that many of the tests included in those domains are verbal
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Table 5 Independent effect of risk factor on cognitive domain and global cognition scores
Risk factor
Maximum No. of
studies
Attention and processing
speed Memory Language Perceptual motor
Frontal executive
function Global cognition
Effect size (95% CI);
p value
Effect size (95% CI);
p value
Effect size (95% CI);
p value
Effect size (95% CI);
p value
Effect size (95% CI);
p value
Effect size (95% CI);
p value
Hypertension 11 −0.15 (−0.29, −0.02); 0.023 −0.09 (−0.19, 0.02); 0.11 −0.18 (−0.29, −0.08);
0.001
−0.17 (−0.31, −0.04);
0.011
−0.18 (−0.31, −0.06);
0.004
−0.24 (−0.38, −0.11);
0.001
Diabetes mellitus 11 −0.46 (−0.61, −0.32); <0.001 −0.25 (−0.35, −0.14);
<0.001
−0.25 (−0.35, −0.14);
<0.001
−0.36 (−0.49, −0.22);
<0.001
−0.33 (−0.47, −0.20);
<0.001
−0.53 (−0.67, −0.40);
<0.001
Smoking (ever) 11 −0.06 (−0.21, 0.09); 0.42 −0.11 (−0.22, −0.002);
0.046
0.01 (−0.11, 0.13); 0.86 −0.21 (−0.35, −0.08);
0.002
0.01 (−0.12, 0.14); 0.88 −0.11 (−0.26, 0.03); 0.13
Atrial fibrillation 11 −0.26 (−0.44, -0.08); 0.005 −0.02 (−0.16, 0.13); 0.82 −0.06 (−0.20, 0.09); 0.42 −0.13 (−0.31, 0.05); 0.15 −0.22 (−0.40, −0.05);
0.014
−0.22 (−0.40, −0.03); 0.02
History of past
stroke
11 −0.51 (−0.68, −0.33); <0.001 −0.18 (−0.31, −0.05);
0.009
−0.28 (−0.42, −0.14);
<0.001
−0.38 (−0.54, −0.21);
<0.001
−0.36 (−0.53, −0.20);
<0.001
−0.50 (−0.67, −0.33);
<0.001
CHF 5 −0.53 (−0.91, −0.16); 0.006 −0.35 (−0.60, −0.10);
0.008
−0.46 (−0.77, −0.15);
0.004
−0.46 (−0.78, −0.14);
0.005
−0.48 (−0.79, −0.18);
0.002
−0.62 (−0.99, −0.25);
0.001
Angina 4 −0.01 (−0.28, 0.27); 0.97 0.06 (−0.12, 0.25); 0.51 −0.10 (−0.29, 0.16); 0.56 0.04 (−0.21, 0.29); 0.76 −0.08 (−0.32, 0.15); 0.50 −0.004 (−0.27, 0.26); 0.98
MI 4 −0.05 (−0.32, 0.23); 0.74 0.004 (−0.23, 0.23); 0.97 −0.06 (−0.28, 0.16); 0.57 −0.02 (−0.27, 0.23); 0.88 −0.07 (−0.30, 0.17); 0.58 −0.02 (−0.28, 0.25); 0.91
Abbreviations: CHF = congestive heart failure; CI, confidence interval; MI = myocardial infarction.
Each model adjusted for sex, age, and education but no other risk factors. North East Melbourne Stroke Incidence Study (NEMESIS) and Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) were not included.
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Figure 2 Forest plots of effect of risk factors on cognitive function in global cognition
These 2-stage meta-analyses were used to examine the degree of variability across studies. For pooled effect sizes (ESs), refer to results from the 1-stage
meta-analyses presented in table 5 (for global cognition) and data available from Dryad (appendix T15, doi.org/10.5061/dryad.m517990, for results in the 5
domains). CASPER = Cognition and Affect After Stroke: Prospective Evaluation of Risks; CI = confidence interval; COAST = Cognitive Outcome After Stroke;
COGFAST-Nigeria = Cognitive Function After Stroke Nigeria; EpiUSA = Epidemiologic Study of the Risk of Dementia After Stroke; GECOG-VASC = Groupe de
Re´flexion pour l’evaluation Cognitive Vasculaire Study; K-VCIHS = Korean-Vascular Cognitive Impairment Harmonization Standards Study; NEMESIS = North
EastMelbourne Stroke Incidence Study; NNI = National Neuroscience Institute Study; PROSPER = Prospective Study of Pravastatin in the Elderly at Risk; SAM=
Helsinki Stroke Aging Memory Study; SSS = Sydney Stroke Study; STROKDEM = Study of Factors Influencing Post-Stroke Dementia; VCI = Vascular Cognitive
Impairment.
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such as the Rey Auditory Verbal Learning Test and the verbal
ﬂuency test.
Our results did not reveal any signiﬁcant diﬀerences in do-
main impairment among ethnoracial groups, a ﬁnding that
may have been inﬂuenced by the small number of studies that
included certain nonwhite groups. The inclusion of additional
nonwhite cohorts will be necessary for future studies to ex-
amine inter-ethnoracial diﬀerences in the prevalence and
potential causes of PSCI.
Our study conﬁrms previous reports that a history of stroke is
one of the strongest predictors of cognitive decline.2 In-
terestingly, we also found that diabetes mellitus was a strong
and signiﬁcant risk factor for impairment in all domains. A
previous review noted the association between diabetes
mellitus and vascular cognitive impairment, although the
magnitude of eﬀect (−0.5 SD in our analysis) was not
described.8
Hypertension is a leading risk factor for stroke, and current
evidence has shown that hypertension in midlife is associ-
ated with an increased risk of dementia.18,19 However, the
evidence on the eﬀects of hypertension later in life is less
clear.20 Our study showed a signiﬁcant association between
hypertension and poorer global cognition, but the associa-
tions with the individual domains, although consistently
negative, did not reach statistical signiﬁcance. Because our
study is cross-sectional, we were unable to assess potential
diﬀerential eﬀects of midlife and late-life hypertension or to
examine the eﬀect of the duration of hypertension on
cognition.
A 2015 review found that current smokers compared with
those who had never smoked showed a 38% increased risk of
vascular dementia.21 Our results showed that smoking was
negatively associated with perceptual motor performance,
which agrees with a review that suggested that the eﬀect of
smoking may be domain speciﬁc.8 While we combined cur-
rent and past smokers in our analysis, further studies should
examine current vs past vs never smokers and the number of
cigarettes smoked.
Recent studies have shown that AF is associated with
a higher risk of cognitive impairment in both stroke and
nonstroke populations.22 Our study showed that AF may be
a risk factor for cognitive impairment, but its eﬀects were
explained by stroke subtype, namely the occurrence of car-
dioembolic stroke, which tends to more severe. This is
consistent with the increased risk of cardioembolic strokes in
patients with AF.
A recent meta-analysis reported coronary heart disease to be
associated with an increased risk of cognitive impairment or
dementia.23 However, we did not ﬁnd evidence of an associ-
ation between coronary artery disease, as manifested by an-
gina and MI, and cognition. Our data showed that CHF was
associated with impaired cognition, although not in-
dependently of other risk factors, but the power to test this
association was limited.
While some patients with TIA may have truly transient
symptomatology, TIA is associated with increased risk of
stroke and concomitant cognitive impairment. Neuroimaging
studies have shown that a clinically diagnosed TIA may be
associated with preexisting brain infarct and other ischemic
changes.24 We note that only 2 studies in the combined
analyses included patients with TIA (4%); at the same time,
the diagnoses of TIA may diﬀer across our studies due to
diﬀerent deﬁnitions used and the quality of information
available. We addressed these issues by performing a sensi-
tivity analysis that showed that the results were the same with
and without patients with TIA.
We found no evidence that the eﬀects of risk factors diﬀered
by sex, age, or educational level; however, we noted signiﬁcant
diﬀerences in their eﬀects on cognitive function between
whites, Koreans, and Chinese, suggesting that risk factors may
have a variable inﬂuence on cognition in diﬀerent ethnoracial
groups. Some studies have identiﬁed racial diﬀerences in de-
mentia risk in American communities in association with
certain vascular risk factors,25,26 yet the literature on in-
terethnic diﬀerences across geographic regions is extremely
limited.
Our analyses that included controls suggested that, while
hypertension, diabetes mellitus, AF, and smoking were asso-
ciated with poorer cognition after stroke, the nature of those
associations was not diﬀerent in participants without stroke.
This indicates that prevention methods used in stroke and
stroke-free populations regarding these risk factors could lead
to similar outcomes, although the eﬃcacy of those inter-
ventions could diﬀer between those 2 groups.
Despite our studies having diﬀerent inclusion/exclusion cri-
teria and being geographically diverse, the heterogeneity in
the risk factor analyses is generally low, and the prevalences of
cognitive impairment are comparable across studies, except
for slightly higher proportions observed in SAM. This may
have been the result of SAM being an older study that used
a comparison group that, with only 38 participants, might not
have been a truly representative normative sample.
Strengths of our study include the operationalized deﬁnition
of cognitive impairment, the standardization of data across
diverse international cohorts, and the more detailed and ro-
bust ﬁndings that arise from IPD meta-analyses. Our study
also has several limitations, some of which apply to poststroke
studies in general. First, patients with cognitive impairment
might be less willing or able to participate, and individuals
with severe language impairment or those who are very ill are
generally excluded, leading to some selection bias. Second,
there is no consensus on the allocation of neuropsychological
tests into domains because neuropsychological tests are
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multifactorial and therefore domains may overlap. Third,
some studies have only 1 test per domain, making the domain
scores less reliable. Fourth, the standardization of test scores
relies on the assumption that the comparison group used for
a particular study is representative of its patient group and of
adequate size; thus, the domain scores and proportions of
impairment could be biased by the nature of the comparison
group. Fifth, risk factor history was generally based onmedical
record review, and there could have been diﬀerences in how it
was recorded across studies. Sixth, while the inclusion of MRI
data would have permitted amore rigorous examination of the
relationship between stroke characteristics and PSCI, MRI
was performed on only a subset of patients, and the harmo-
nization of imaging data would have been beyond the scope of
the present study. Finally, 3 studies in our combined analyses
did not attempt to exclude patients with known dementia, but
all studies may have included some patients with preexisting
dementia because no clinical assessments were performed
until after the index stroke and patient recruitment, which
could have led to overestimation of the frequency of cognitive
impairment.
Despite those limitations, we believe that this work presents
a robust analysis that draws on the strengths of the contrib-
uting studies and provides valuable information on stroke as
a basis for cognitive impairment.
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